Searched for
BIOPHARMACEUTICAL INDUSTRY INDIA
NITI Aayog proposes pharma chapter for future FTAs, urges India to move up value chainNiti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...- Why the world is betting on China again, and what India must do about itChina's business environment prioritizes market share with strong government backing. The nation has shifted to high-quality, high-speed pr...
- Govt outlines next phase of pharma growthThe government highlighted its achievements, reforms, and policy initiatives, aiming to boost exports from $31 billion to $50 billion by 20...
- More macro headwinds on the cards? Tackle them with core principles: 6 pharma stocks with upside potential of up to 28%There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsAs far as India is concerned, the biggest pain point from the US-Iran war in the Gulf region has been the spike in the prices of not only o...
- The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...
- War, oil price hikes, and risks: Time to still be contrarian? 5 small-caps from different sectors with upside potential of up to 25%Small-cap investing is not just about finding stocks that can rise faster than the market, which is the assumption with which most investor...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Semaglutide API price plunges amid GLP-1 rushGlobal demand for weight-loss drugs Ozempic and Wegovy has caused semaglutide prices to drop significantly. Manufacturing has expanded rapi...
- India is well positioned to attract future investments, says Eli Lilly's Patrik JonssonEli Lilly's Patrik Jonsson urges India to accelerate regulatory review pathways to boost competitiveness, emphasizing the need for data pro...
- AstraZeneca India recasts biopharma unitAstraZeneca India has laid off over 125 employees in its biopharmaceutical business unit, including senior managers and sales executives. T...
- A growth formula for generics, biosimilarsUnder the scheme, financial incentives will be given to eligible manufacturers of complex generics and biopharmaceuticals on their sales ov...
- National Biopharma Mission launchedNew Delhi, June 30 (IANS) The National Biopharma Mission aimed at accelerating biopharmaceutical development in the country was launched by...
- India launches flagship program to boost biopharma productionThe ministry, which has received a loan of $125 million (over Rs 800 crore) from the World Bank for its “Innovate in India” (i3) program, h...
- Government clears mission to develop bio-pharmaceuticalsThe 'Innovate in India empowering biotech entrepreneurs and accelerating inclusive innovation' mission will strengthen domain specific know...
- Incoming Narendra Modi government represents opportunity to US business: PhRMAIncoming Modi-led govt represents an 'excellent opportunity' for American industries to strengthen & rekindle their relationships with Indi...
- India emerges as leader in global vaccine market: GovernmentIndia has emerged as a global leader in vaccines with about one-third share of the total market, a senior government official said today.
- India's biotech sector to grow 20% in foreseeable futureMazumdar-Shaw said the size of the country's biotech sector had reached USD 3.5 billion in 2010 and is poised for robust growth in all segm...
- GE Healthcare to acquire PAA LaboratoriesGE Healthcare said that it has reached an agreement to acquire PAA Laboratories that develops and supplies cell culture media for biomedica...
- Recession not to hit clinical trials: CROsIndian clinical research organisations do not see any near-term impact of recession as large pharma customers such as AstraZeneca and Glaxo...
Load More
